Giammarile Francesco, Chiti Arturo, Lassmann Michael, Brans Boudewijn, Flux Glenn
CH Lyon Sud, EA 3738, HCL, UCBL, 165 Chemin du Grand Revoyet, 69495, Pierre Benite Cedex, France.
Eur J Nucl Med Mol Imaging. 2008 May;35(5):1039-47. doi: 10.1007/s00259-008-0715-3.
Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called "false" neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system. The neuroendocrine system is derived from a family of cells originating in the neural crest, characterized by an ability to incorporate amine precursors with subsequent decarboxylation. The purpose of this guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.
间碘苄胍，或称为碘苄胍，是一种芳烷基胍，由溴苄铵的苄基与胍乙啶（一种肾上腺素能神经元阻滞剂）的胍基结合而成。它是去甲肾上腺素（去甲肾上腺素）类似物，即所谓的“假”神经递质。这种用131I标记的放射性药物可作为神经外胚层肿瘤的放射治疗代谢剂，神经外胚层肿瘤源自发育形成交感神经系统的原始神经嵴。神经内分泌系统源自起源于神经嵴的一类细胞，其特征是能够摄取胺前体并随后进行脱羧。本指南的目的是协助核医学从业者评估可能适合用131I - 间碘苄胍治疗神经外胚层肿瘤的患者，提供进行该治疗的信息，并了解和评估治疗的后果。
